Hutchin Hill Capital’s Meridian Bioscience Inc VIVO Stock Holding History

Hutchin Hill Capital’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-36,700	Closed	-$578K	–	1022
2017 Q2	$578K	Buy	+36,700	New	+$529K	0.02%	652
2015 Q2	–	Sell	-60,500	Closed	-$1.15M	–	847
2015 Q1	$1.15M	Buy	60,500 +17,400	+40%	+$322K	0.03%	417
2014 Q4	$709K	Buy	+43,100	New	+$739K	0.03%	396

Other funds holding VIVO

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Hutchin Hill Capital's VIVO Position: Q3 2017 in Review

Hutchin Hill Capital sold out of Meridian Bioscience Inc (VIVO) in Q3 2017, closing a stake of 36,700 shares — an estimated $578K sold.

Hutchin Hill Capital first reported a position in VIVO in Q4 2014 and held it in 3 quarters. The position peaked at $1.15M in Q1 2015. 172 funds tracked by Wall St. Rank hold VIVO as of Q3 2017.

Hutchin Hill Capital reported no remaining Meridian Bioscience Inc position as of Q3 2017 after selling out during the quarter.
Hutchin Hill Capital sold 36,700 Meridian Bioscience Inc shares in Q3 2017, an estimated $578K.
Hutchin Hill Capital first reported a position in Meridian Bioscience Inc in Q4 2014 and held it in 3 quarters.
Hutchin Hill Capital's Meridian Bioscience Inc position peaked at $1.15M in Q1 2015.
172 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2017.

Based on Hutchin Hill Capital's 13F filing for Q3 2017, filed 14 Nov 2017.